2021
Expected Medium- and Long-Term Impact of the COVID-19 Outbreak in Oncology
Onesti CE, Tagliamento M, Curigliano G, Harbeck N, Bartsch R, Wildiers H, Tjan-Heijnen V, Martin M, Rottey S, Generali D, Campone M, Cristofanilli M, Pusztai L, Peeters M, Berchem G, Cortes J, Ruhstaller T, Ciruelos E, Rugo HS, Jerusalem G. Expected Medium- and Long-Term Impact of the COVID-19 Outbreak in Oncology. JCO Global Oncology 2021, 7: go.20.00589. PMID: 33529077, PMCID: PMC8081548, DOI: 10.1200/go.20.00589.Peer-Reviewed Original ResearchConceptsMedical oncologistsCOVID-19 positive patientsCOVID-19 outbreakUse of telemedicineClinical trial activityAffected modalityPalliative treatmentOncology unitLong-term impactNational registryPostacute phaseClinical activityMultidisciplinary meetingOncologic activityLocal registryHealthcare staffTreatment adaptationPatientsEarly cessationTrial activityHealthcare systemCOVID-19 pandemicOncologistsRegistrySignificant reduction
2011
Biomarker studies: a call for a comprehensive biomarker study registry
Andre F, McShane LM, Michiels S, Ransohoff DF, Altman DG, Reis-Filho JS, Hayes DF, Pusztai L. Biomarker studies: a call for a comprehensive biomarker study registry. Nature Reviews Clinical Oncology 2011, 8: 171-176. PMID: 21364690, DOI: 10.1038/nrclinonc.2011.4.Peer-Reviewed Original Research